EPAS1 and nonpapillary renal cell carcinoma: Currently, six ongoing clinical trials are investigating the safety and efficacy of HIF-2α inhibition in combination with ICB (pembrolizumab) for advanced ccRCC or solid tumors (NCT04976634, NCT05239728, NCT05030506, NCT05899049, NCT04736706, and NCT04895748).